| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 629 companies in the Biotechnology industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 29, 2026 | VRTX Vertex Pharmaceuticals Incorporated | Bozic Carmen53 | EVP And CMO | Sell | 1,974 | $450.00 | $888,300.00 | -8.0% | - | - | |
| May 29, 2026 | PCSA Processa Pharmaceuticals, Inc. | Skibsted Russell | Chief Financial Officer | Buy | 2,292 | $2.57 | $5,890.44 | +27.1% | - | - | |
| May 29, 2026 | GLUE Monte Rosa Therapeutics, Inc. | Townson Sharon | Chief Scientific Officer | Sell | 6,000 | $19.87 | $119,220.00 | -8.1% | - | - | |
| May 29, 2026 | CMMB Chemomab Therapeutics Ltd. | Mor George Adi | Chief Executive Officer | Buy | 9,804 | $2.07 | $20,245.98 | +3.7% | - | - | |
| May 29, 2026 | PCSA Processa Pharmaceuticals, Inc. | Lin Patrick | Chief Business - Strategy Off | Buy | 1,582 | $2.57 | $4,065.74 | +20.8% | - | - | |
| May 29, 2026 | ANTX An2 Therapeutics, Inc. | Williams Sarah Joanne | Principal Accounting Officer | Sell | 265 | $4.43 | $1,173.95 | -0.4% | - | - | |
| May 29, 2026 | ASND Ascendis Pharma A/s | Smith Scott Thomas | EVP &Chief Financial Officer | Buy | 250 | $223.32 | $55,830.00 | +6.2% | - | - | |
| May 29, 2026 | PCSA Processa Pharmaceuticals, Inc. | Guy Wendy | Chief Administrative Officer | Buy | 1,829 | $2.57 | $4,700.53 | +22.8% | - | - | |
| May 29, 2026 | MAZE Maze Therapeutics, Inc. | Dandekar Atul | Csbo | Sell | 7,500 | $26.34 | $197,553.75 | -23.2% | - | - | |
| May 29, 2026 | MDWD Mediwound Ltd. | Rubinstein Samuel45 | Director | Buy | 150 | $14.33 | $2,149.50 | +5.3% | - | - | |
| May 29, 2026 | KRRO Korro Bio, Inc. | Aiyar Ram | President And CEO | Sell | 15,152 | $12.98 | $196,672.96 | -16.8% | - | - | |
| May 29, 2026 | PCSA Processa Pharmaceuticals, Inc. | Young David | Pres. Research &Development | Buy | 1,786 | $2.57 | $4,590.02 | +11.6% | - | - | |
| May 29, 2026 | PTGX Protagonist Therapeutics, Inc. | Waddill William D.50 | Director | Sell | 9,000 | $99.64 | $896,760.00 | -53.5% | - | - | |
| May 29, 2026 | CNTB Connect Biopharma Holdings Limited | Huang James | Director | Buy | 150,000 | $2.48 | $371,610.00 | +1.1% | - | - | |
| May 29, 2026 | ILMN Illumina, Inc. | Davies Scott M | Chief Legal Officer | Sell | 615 | $160.00 | $98,400.00 | -2.8% | - | - | |
| May 29, 2026 | ILMN Illumina, Inc. | Ericksen Scott D | VP, Chief Accounting Officer | Sell | 2,000 | $152.58 | $305,150.00 | -6.4% | - | - | |
| May 29, 2026 | CRSP Crispr Therapeutics AG | Patel Naimish | Chief Medical Officer | Sell | 3,786 | $55.62 | $210,577.32 | -16.4% | - | - | |
| May 29, 2026 | ACOG Alpha Cognition Inc. | Opaleye Management Inc.60 | 10% Owner | Buy | 73,738 | $5.90 | $434,713.77 | +1.0% | - | - | |
| May 28, 2026 | EVMN Evommune, Inc. | Carver Kyle | Chief Financial Officer | Sell | 18,175 | $22.84 | $415,117.00 | -23.4% | - | - | |
| May 28, 2026 | NUVL Nuvalent, Inc. | Miller Deborah Ann | Chief Legal Officer | Sell | 5,500 | $107.84 | $593,100.52 | -2.2% | - | - | |
| May 28, 2026 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | Sell | 679 | $16.00 | $10,864.00 | -1.4% | - | - | |
| May 28, 2026 | EQ Equillium, Inc. | Tom Penny | Principal Accounting Officer | Sell | 65,000 | $2.95 | $191,750.00 | -100% | - | - | |
| May 28, 2026 | EVMN Evommune, Inc. | Moss Gregory S. | Chief Business &Legal Officer | Sell | 14,223 | $22.83 | $324,711.09 | -18.9% | - | - | |
| May 28, 2026 | PGEN Precigen, Inc. | Lehr Donald P.75 | Chief Legal Officer | Sell | 29,131 | $4.36 | $127,011.16 | -3.7% | - | - | |
| May 28, 2026 | PGEN Precigen, Inc. | Sabzevari Helen75 | President And CEO | Sell | 119,250 | $4.36 | $519,930.00 | -3.1% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.